• Tel : +98 (21) 44787039
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Leupromer® 7/5


Image

Prostat cancer
Your Care, Supported by Our Commitment

Leuprolide is the #1 prescribed drug in its class in the US* for the treatment of advanced prostate cancer.
Leupromer® 7.5 mg suppresses the testosterone that causes testosterone-dependent prostate cancer cells to grow.
Leuprolide acetate is a GnRHa, which is widely used for the treatment of hormone-dependent conditions in men and women.
A chronic administration of a GnRHa leads to downregulation of GnRH receptors in the pituitary gland, which results in a complete suppression of luteinizing hormone (LH), follicle- stimulating hormone and gonadal steroids after an initial stimulatory phase (hormonal flare). Usually within 4 weeks of initiation of leuprolide acetate therapy, serum testosteroneis reduced to near surgically castrated levels.

 


WOMEN
Endometriosis

 

Leuprolide is promoted within the gynecological field as one of the best options for treating endometriosis.
Leupromer® 7.5 mg for 1-month administration is used the management of endometriosis, including pain relief and reducation of endometriotic lesions.
 Leupromer® 7.5 mg with daily norethindrone acetate 5 mg (Add-back*) is also indicated for initial management of ndometriosis and for management of recurrence of symptoms.
Endometriosis: 10% of women who are of child-bearing age, is a gynecologic disorder defined by the presence of endometrial-like tissue located outside of the uterine or  endometrial cavity. These lesions are typically found on the ovaries but have been known to grow in many other areas of the pelvic peritoneum Endometriosis accounts for 15-25% of the pelvic pain experienced by women and correlates with the major symptom of dysmenorrhea.
The recommended initial treatment is no more than 6 month. Repeat treatment for endometriosis should be limited to 6 months.

Fibroids

Leupromer® 7.5 mg for 1-month administration with iron therapy are used before Fibroid surgery to improve anemia due to vaginal bleeding from Fibroids. Most of doctors may consider a one-month trial of iron alone as some patients anemia will improve with iron alone. It is recommended that Leupromer® 7.5 mg not be used for more than 3 months in patients with Fibroids.
Fibroids, are benign tumors that arise from smooth muscle cells located within the uterus. Myomas are known to be the most common benign tumor and occur in 20-50% of women during their reproductive period. Much as with endometriosis, the symptoms observed include pelvic pressure/pain, dysmenorrhea, bleeding and dysfunction of the reproductive and adjacent organs. Myomas are responsible for 40% of hydsterectomies performed in the US. As with endometriosis, these tumars are responsive to their hormonal environment and therefore hormones sup-pression using GnRH agonists, especially leuprolide acetate, hs used in the management of this disease. Leuprolide acetate is typically used as a preoperative measure to shrink tumor size.
Leuprolide acetate is thought tosuppress estradiol andprogesterone signaling in reducing uterine leiomyoma size.

Central Precocious Puberty (CPP)


Leupromer® 7.5 mg for 1-month administration is prescribed for the treatment of children with central precocious puberty (CPP).
Leuprolide Acetate is the #1 prescribed treatment for central Puberty (CPP) in USA1
Pause early Puberty.
                        Continue childhood.
Leupromer® 7.5 mg for 1-month provides the effective suppression they need

During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the initial symptoms of Puberty may be observed.
Psychiatric events have been reported in patients taking GnRH agonists, including Leupromer® 7.5 mg. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Monitor for development or worsening of psychiatric symptoms during treatment.

References1: IMS Health, IMS National Prescription Audit, june 2016.

 

 

Image

Copyright © 2019 Varian Pharmed. All rights reserved